HER2+ Unresectable or Metastatic | Norton Healthcare

Indication: HER2+ Unresectable or Metastatic

Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)

Sub-indication: Breast Cancer

Study Type: Drug Study

Principal Investigator: Laila Agrawal, M.D.
Norton Cancer Institute

Sponsor: Sponsor: AstraZeneca

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.